{"id":21260,"date":"2023-03-09T13:57:00","date_gmt":"2023-03-09T05:57:00","guid":{"rendered":"https:\/\/flcube.com\/?p=21260"},"modified":"2025-01-11T14:01:42","modified_gmt":"2025-01-11T06:01:42","slug":"biocytogen-and-janssen-sign-licensing-agreement-for-renlite-platform-2","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21260","title":{"rendered":"Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform"},"content":{"rendered":"\n

Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315<\/a>) has announced the signing of a non-exclusive licensing agreement with Janssen Biotech Inc., a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ<\/a>). The agreement, facilitated by Johnson & Johnson Innovation LLC, grants Janssen and its affiliates a non-exclusive worldwide license to utilize Biocytogen\u2019s proprietary RenLite platform and associated intellectual property. This collaboration aims to discover, research, develop, manufacture, and commercialize fully human antibody therapeutics with a common light chain, as well as other biological therapeutics, for an unlimited number of drug targets and indications. Financial terms of the agreement were not disclosed.<\/p>\n\n\n\n

About the RenLite Platform<\/strong>
RenLite is an integral part of Biocytogen’s fully human antibody RenMice family. This innovative platform enables the generation of fully human antibody candidates that exhibit high specificity, affinity, diversity, and good druggability. A distinctive feature of RenLite mice is their ability to produce antibodies with a common light chain, which is crucial for the subsequent assembly of bispecific and multi-specific antibodies. This approach results in a low mismatch rate and a high success rate, making it an attractive option for the development of complex therapeutics.<\/p>\n\n\n\n

Advantages for Therapeutics Development<\/strong>
The bispecific and multi-specific antibodies developed through the RenLite platform maintain a traditional antibody structure. This characteristic is beneficial as it ensures ideal physiochemical properties, which are advantageous for downstream chemical, manufacturing, and control (CMC) development. The agreement with Janssen Biotech Inc. underscores the potential of the RenLite platform to contribute significantly to the advancement of antibody therapeutics globally.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[1519,1214,107,150,149,858],"class_list":["post-21260","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-biocytogen-pharmaceuticals","tag-hkg-2315","tag-immunotherapy","tag-jj","tag-johnson-johnson","tag-nyse-jnj"],"yoast_head":"\nBiocytogen and Janssen Sign Licensing Agreement for RenLite Platform - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing agreement with Janssen Biotech Inc., a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ). The agreement, facilitated by Johnson & Johnson Innovation LLC, grants Janssen and its affiliates a non-exclusive worldwide license to utilize Biocytogen\u2019s proprietary RenLite platform and associated intellectual property. This collaboration aims to discover, research, develop, manufacture, and commercialize fully human antibody therapeutics with a common light chain, as well as other biological therapeutics, for an unlimited number of drug targets and indications. Financial terms of the agreement were not disclosed.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21260\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21260\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-03-09T05:57:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-11T06:01:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21260#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21260\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform\",\"datePublished\":\"2023-03-09T05:57:00+00:00\",\"dateModified\":\"2025-01-11T06:01:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21260\"},\"wordCount\":267,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Biocytogen Pharmaceuticals\",\"HKG: 2315\",\"Immunotherapy\",\"J&J\",\"Johnson & Johnson\",\"NYSE: JNJ\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21260#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21260\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21260\",\"name\":\"Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-03-09T05:57:00+00:00\",\"dateModified\":\"2025-01-11T06:01:42+00:00\",\"description\":\"Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing agreement with Janssen Biotech Inc., a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ). The agreement, facilitated by Johnson & Johnson Innovation LLC, grants Janssen and its affiliates a non-exclusive worldwide license to utilize Biocytogen\u2019s proprietary RenLite platform and associated intellectual property. This collaboration aims to discover, research, develop, manufacture, and commercialize fully human antibody therapeutics with a common light chain, as well as other biological therapeutics, for an unlimited number of drug targets and indications. Financial terms of the agreement were not disclosed.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21260#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21260\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21260#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform - Insight, China's Pharmaceutical Industry","description":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing agreement with Janssen Biotech Inc., a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ). The agreement, facilitated by Johnson & Johnson Innovation LLC, grants Janssen and its affiliates a non-exclusive worldwide license to utilize Biocytogen\u2019s proprietary RenLite platform and associated intellectual property. This collaboration aims to discover, research, develop, manufacture, and commercialize fully human antibody therapeutics with a common light chain, as well as other biological therapeutics, for an unlimited number of drug targets and indications. Financial terms of the agreement were not disclosed.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21260","og_locale":"en_US","og_type":"article","og_title":"Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=21260","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-03-09T05:57:00+00:00","article_modified_time":"2025-01-11T06:01:42+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21260#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21260"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform","datePublished":"2023-03-09T05:57:00+00:00","dateModified":"2025-01-11T06:01:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21260"},"wordCount":267,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Biocytogen Pharmaceuticals","HKG: 2315","Immunotherapy","J&J","Johnson & Johnson","NYSE: JNJ"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21260#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21260","url":"https:\/\/flcube.com\/?p=21260","name":"Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-03-09T05:57:00+00:00","dateModified":"2025-01-11T06:01:42+00:00","description":"Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced the signing of a non-exclusive licensing agreement with Janssen Biotech Inc., a subsidiary of Johnson & Johnson (J&J, NYSE: JNJ). The agreement, facilitated by Johnson & Johnson Innovation LLC, grants Janssen and its affiliates a non-exclusive worldwide license to utilize Biocytogen\u2019s proprietary RenLite platform and associated intellectual property. This collaboration aims to discover, research, develop, manufacture, and commercialize fully human antibody therapeutics with a common light chain, as well as other biological therapeutics, for an unlimited number of drug targets and indications. Financial terms of the agreement were not disclosed.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21260#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21260"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21260#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Biocytogen and Janssen Sign Licensing Agreement for RenLite Platform"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21260"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21260\/revisions"}],"predecessor-version":[{"id":21261,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21260\/revisions\/21261"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21260"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}